Dossier Acceptance and Payment Process at the Sri Lanka NMRA
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Sri Lankan acceptance and payment chain runs in four steps. First, the applicant submits the complete dossier to the acceptance point. Second, the accepting officer checks the existence and completeness of the documents against the submission checklist, with the content left for later evaluation. Third, once the check passes, a payment note is issued. Fourth, the applicant pays at the NMRA Accounts Division and, presenting the yellow receipt together with the dossier, returns to the acceptance point, where the officer verifies the receipt, assigns the dossier number and issues the receipt confirmation. Each step unlocks the next, so a file that fails the existence-and-completeness check never reaches the payment stage at all. Understanding this before travelling to the NMRA prevents the common mistake of treating acceptance as a formality that can be improvised at the counter.
- Document check: the accepting officer verifies completeness against the submission checklist, under GL-034 (effective 23 July 2025).
- Scope of the check: only existence and completeness; content is left for subsequent evaluation.
- Basis of payment: the application type (site registration or product registration) and the information provided by the local agent in the online form, per the NMRA website procedure description.
- Place of payment: the NMRA Accounts Division.
- Voucher: a yellow receipt is issued after payment.
- Dossier number: assigned by the accepting officer once the yellow receipt is presented with the dossier.
- Monthly fee schedule: the NMRA publishes a monthly medical device fee schedule, with amounts updated monthly.
2. Legal basis
The acceptance and payment procedure is documented in GL-034, effective 23 July 2025, and in the procedure description on the NMRA website. The table below follows the chain from the document check through payment to the assignment of the dossier number, which is the order in which the steps actually occur at the counter.
A useful way to read the chain is to ask what each step produces. The document check produces the right to pay; payment produces the yellow receipt; the yellow receipt presented with the dossier produces the dossier number and the receipt confirmation. Since each output is the input of the next step, the applicant controls the tempo of the whole chain, and preparing each output in advance keeps the four steps inside a single visit.
| Matter | Content | Source |
| Document check | The accepting officer checks completeness against the submission checklist | GL-034 (effective 23 July 2025) |
| Scope of the check | Only existence and completeness; content is left for subsequent evaluation | Same source |
| Basis of payment | The application type (site registration or product registration) and the information the local agent provides in the online form | NMRA website procedure description |
| Place of payment | The NMRA Accounts Division | Same source |
| Voucher | A yellow receipt is obtained after payment | Same source |
| Dossier number | Assigned by the accepting officer after the yellow receipt is presented | Same source |
| Monthly fee schedule | The NMRA publishes a monthly medical device fee schedule, updated by the month | Same source |
3. Expert insights
Insight one: at acceptance, the officer counts the documents and does not read them. This point is decisive for expectations: acceptance is not evaluation. A dossier being taken in only means that every document is present; whether the product passes depends on the MDEC technical evaluation that follows. Teams should therefore not read an acceptance as a favourable signal about the scientific content, and should keep working on the technical file quality while the payment chain completes.
Insight two: the payment note is issued only after the check passes. This creates the chain of completeness first, payment second, dossier number third. With incomplete documents, the applicant cannot even obtain a number, and the project cannot be tracked. The number is what anchors every later correspondence, deficiency response and progress query, so the practical cost of an incomplete package is not just a lost Tuesday but the loss of a trackable project identity.
Insight three: fees are updated monthly, so quotations have an expiry. What the NMRA publishes is a monthly fee schedule. Every rupee amount must therefore be tagged with the month it belongs to; otherwise it is outdated information (see Article 34). Budgets, quotations to clients and internal approval documents that quote a fee without its month invite disputes when the schedule changes, and the schedule does change.
4. Practical recommendations
- Prepare two sets of material for the acceptance stage: a day-of-acceptance checklist, arranged item by item according to the official checklist and ticked off on the spot, and a payment voucher file holding the payment note, the bank slip and the scanned yellow receipt.
- Retain the originals of both, because these documents are the basis for every later progress query and dispute, and copies alone carry little weight in an argument.
- Confirm the application type and the local agent’s online form information before payment, since these determine the amount due.
- Record the month of any fee figure wherever it appears, from internal budgets to client quotations.
- Treat the dossier number and the receipt confirmation as the closing milestones of the acceptance stage and file them immediately in the project record.
5. Verification checklist
- □ The item-by-item self-check has been completed against the official submission checklist
- □ The payment note issued by the accepting officer has been obtained
- □ Payment has been completed and the yellow receipt retained
- □ The dossier number and receipt confirmation have been obtained in exchange for the receipt
- □ The payment voucher file has been established
- □ The current monthly fee schedule has been checked
- □ Every fee figure in the project documents is tagged with its month
- □ The originals of the checklist and the payment vouchers are stored together with the project record
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Regulatory information verified as of 28 October 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us